文献速递肺栓塞与肺血管病

肺动脉高压的遗传学与精准基因组学方法

Genetics and precision genomics approaches to pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2024-10-31

自第六届世界肺动脉高压研讨会以来,动脉性肺动脉高压(PAH)基因组学进展显著,识别了多个新基因的罕见变异及增加PAH风险的常见变异。专家组的基因与变异管理为临床实践中检测哪些基因及如何解读变异提供了框架。建议对特定亚组的有症状PAH患者及某些类型第3组肺动脉高压儿童提供基因检测。

要点

  • 建议对特定亚组有症状PAH患者及某些第3组肺动脉高压儿童提供基因检测。
  • 无症状家族成员检测及生殖决策中的遗传学应用需遗传学专家参与。
  • 现有PAH患者大型生物样本队列多为欧洲来源,需增加多样性以全面刻画基因组变异。

核心结论

  • PAH基因组学进展显著,专家管理的基因与变异框架有助于临床检测与解读。
  • 建议对特定亚组有症状PAH患者及某些第3组肺动脉高压儿童提供基因检测。
  • 基因特异性注册登记对推进基因与通路特异性护理及靶向治疗至关重要。

研究设计与样本

  • 本文为综述,总结自第六届世界肺动脉高压研讨会以来的PAH基因组学进展。

主要发现

  • 识别了多个新基因的罕见变异及增加PAH风险的常见变异。
  • 专家组的基因与变异管理提供了临床实践中检测与解读变异的框架。
  • 大型PAH患者生物样本队列已存在,并已开始扩展至非第1组肺动脉高压。
  • 这些队列大多为欧洲来源,需更大多样性以刻画基因组变异全貌。
  • 其他类型组学数据正被整合,基因特异性注册登记将支持患者及家庭。

关键数值与推荐

  • 建议对特定亚组有症状PAH患者提供基因检测。
  • 建议对某些类型第3组肺动脉高压儿童提供基因检测。
  • 无症状家族成员检测及生殖决策中的遗传学应用需遗传学专家参与。

临床怎么用

  • 临床可依据专家管理的基因与变异框架选择检测基因并解读变异。
  • 对特定亚组有症状PAH患者及某些第3组肺动脉高压儿童提供基因检测。
  • 涉及无症状家族成员检测或生殖决策时需遗传学专家参与。

局限性

  • 现有大型PAH患者生物样本队列大多为欧洲来源,多样性不足。
  • 需国际推广及患者、家庭、临床医生与研究者之间的合作。
  • 患者来源生物标本、临床与组学信息及分析方法的统一尚待实现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Considerable progress has been made in the genomics of pulmonary arterial hypertension (PAH) since the 6th World Symposium on Pulmonary Hypertension, with the identification of rare variants in several novel genes, as well as common variants that confer a modest increase in PAH risk. Gene and variant curation by an expert panel now provides a robust framework for knowing which genes to test and how to interpret variants in clinical practice. We recommend that genetic testing be offered to specific subgroups of symptomatic patients with PAH, and to children with certain types of group 3 pulmonary hypertension (PH). Testing of asymptomatic family members and the use of genetics in reproductive decision-making require the involvement of genetics experts. Large cohorts of PAH patients with biospecimens now exist and extension to non-group 1 PH has begun. However, these cohorts are largely of European origin; greater diversity will be essential to characterise the full extent of genomic variation contributing to PH risk and treatment responses. Other types of omics data are also being incorporated. Furthermore, to advance gene- and pathway-specific care and targeted therapies, gene-specific registries will be essential to support patients and their families and to lay the foundation for genetically informed clinical trials. This will require international outreach and collaboration between patients/families, clinicians and researchers. Ultimately, harmonisation of patient-derived biospecimens, clinical and omic information, and analytic approaches will advance the field.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Austin ED, Aldred MA, Alotaibi M, et al. Genetics and precision genomics approaches to pulmonary hypertension. Eur Respir J. 2024. PMID: 39209481. doi:10.1183/13993003.01370-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。